NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
The Pharma Letter

Enhertu approved in China for new indication

Enhertu (trastuzumab deruxtecan) has now been approved in China for the treatment of adult patients with unresectable or ...
Pharmabiz

Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer

Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...